^
BIOMARKER:

HER-2 L755S

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 L755S
HER2 Negative Breast Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
HER-2 L755S
Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
HER-2 L755S
Triple Negative Breast Cancer
neratinib
Sensitive: C4 – Case Studies
HER-2 L755S
HER2 Positive Breast Cancer
tucatinib
Resistant: D – Preclinical
HER-2 L755S
CRC
panitumumab
Resistant: D – Preclinical
HER-2 L755S
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Resistant: D – Preclinical
HER-2 L755S
HER2 Positive Breast Cancer
neratinib
Resistant: D – Preclinical
HER-2 L755S
HER2 Positive Breast Cancer
lapatinib
Resistant: D – Preclinical
HER-2 L755S
Gastric Cancer
tucatinib
Sensitive: D – Preclinical
HER-2 L755S
CRC
tucatinib
Sensitive: D – Preclinical
HER-2 L755S
Breast Cancer
ado-trastuzumab emtansine
Resistant: D – Preclinical
HER-2 L755S
NSCLC
tucatinib
Sensitive: D – Preclinical
HER-2 L755S
Gastric Cancer
CL-387785
Sensitive: D – Preclinical
HER-2 L755S
Gastric Cancer
WZ4002
Sensitive: D – Preclinical
HER-2 L755S
CRC
cetuximab
Resistant: D – Preclinical
HER-2 L755S
Breast Cancer
lapatinib
Resistant: D – Preclinical
HER-2 L755S
Breast Cancer
WZ4002
Sensitive: D – Preclinical
HER-2 L755S
Breast Cancer
AEE788
Sensitive: D – Preclinical
HER-2 L755S
Breast Cancer
CL-387785
Sensitive: D – Preclinical
HER-2 L755S
HER2 Negative Breast Cancer
lapatinib
Resistant: D – Preclinical
HER-2 L755S
Gastric Cancer
lapatinib
Resistant: D – Preclinical
HER-2 L755S
Gastric Cancer
AEE788
Sensitive: D – Preclinical